Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Lancet. 2004 Jul;364(9431):365-7. doi: 10.1016/S0140-6736(04)16725-1.


The meningococcal serogroup C conjugate (MCC) vaccine programme in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years). However, for children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vaccine fell to low levels after only 1 year. The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Child
  • Child, Preschool
  • England / epidemiology
  • Follow-Up Studies
  • Humans
  • Immunity, Herd
  • Immunization Schedule
  • Immunization, Secondary
  • Infant
  • Meningococcal Infections / epidemiology
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines* / immunology
  • Neisseria meningitidis, Serogroup C / immunology*
  • Vaccines, Conjugate


  • Meningococcal Vaccines
  • Vaccines, Conjugate